Complete ERA: Phase I–V Framework for Pharmaceuticals

Phase I–V ERA Pharmaceutical Compounds CRO India
Agrochemical & Pharmaceutical ERA

Complete Environmental Risk Assessment: Understanding the Phase I–V ERA Framework

Environmental Risk Assessment (ERA) for pharmaceutical compounds follows a structured, stepwise framework designed to systematically evaluate the potential environmental impact of an active pharmaceutical ingredient (API) or medicinal product.

The framework progresses through defined assessment phases — from an initial Phase I screening evaluation through increasingly detailed Phase II studies covering environmental fate, aquatic ecotoxicology, sediment and terrestrial assessment, and advanced Phase V studies addressing bioaccumulation, food-chain effects, transformation products and final risk characterization.

Accuprec Research Labs supports organizations across the complete Phase I–V ERA framework, providing integrated scientific and regulatory support at every stage of the assessment process.


Framework Overview

The ERA Phase Framework

The ERA framework for pharmaceutical compounds is tiered — each phase builds on the conclusions of the previous one, with the scope and depth of assessment expanding as evidence of potential environmental concern is identified. This approach ensures that resources are focused where the environmental risk is greatest, while allowing straightforward cases to be resolved efficiently at earlier phases.

I

Phase I — Preliminary Assessment

Initial screening based on predicted environmental concentration and compound properties

II

Phase II — Fate & Exposure Assessment

Environmental fate studies and refined PEC estimation across relevant compartments

III

Phase III — Aquatic Ecotoxicology

Ecotoxicological testing for algae, aquatic invertebrates and fish

IV

Phase IV — Sediment & Terrestrial Assessment

Extended assessment for sediment-dwelling organisms and terrestrial compartments

V

Phase V — Advanced Assessment

Bioaccumulation, food-chain effects, transformation products, final PEC/PNEC and risk characterization


I

Phase I — Preliminary Assessment

Phase I is the entry point to the ERA framework. Its purpose is to determine, based on available information, whether a compound has the potential to reach the environment in concentrations that may pose a risk, and whether further assessment is warranted.

The Phase I assessment is based primarily on the calculation of an initial Predicted Environmental Concentration in surface water (PECsurface water), using a default regulatory equation that considers the anticipated daily dose and market penetration factor. This provides a conservative, worst-case screening estimate of potential environmental exposure.

If the PECsurface water falls below the applicable trigger value (0.01 µg/L under EMA guidance), and the compound does not have properties associated with potential environmental concern (such as high log Kow or endocrine-disrupting potential), the ERA may conclude at Phase I with the determination that the compound is unlikely to pose an unacceptable environmental risk.

Phase I covers:

  • Initial PECsurface water calculation
  • Evaluation against Phase I trigger value (0.01 µg/L)
  • Assessment of compound properties relevant to Phase II triggering
  • Determination of whether Phase II assessment is required

II

Phase II — Environmental Fate & Exposure Assessment

Phase II begins the detailed environmental assessment. It introduces environmental fate studies that characterize how the compound behaves in environmental systems, and uses this information to refine environmental exposure estimates.

Fate studies at Phase II typically include hydrolysis, photolysis, ready biodegradability, water/sediment transformation, soil transformation and adsorption/desorption. The data generated from these studies informs PEC estimation for surface water, groundwater, sediment and soil compartments using appropriate regulatory exposure models.

Phase II also includes an initial assessment of PBT/vPvB characteristics based on available persistence, bioaccumulation and toxicity information. If the compound meets screening criteria for PBT/vPvB, further assessment is required regardless of the PEC/PNEC outcome.

Phase II covers:

  • Hydrolysis
  • Photolysis (direct and indirect)
  • Ready biodegradability
  • Water/sediment transformation
  • Soil transformation
  • Adsorption/desorption (Koc)
  • Refined PEC estimation for all relevant compartments
  • Initial PBT/vPvB screening

III

Phase III — Aquatic Ecotoxicology

Phase III introduces ecotoxicological testing to characterize the effects of the compound on aquatic organisms. The aquatic environment is typically the primary focus of ERA for pharmaceutical compounds, as wastewater and surface water pathways represent the most significant routes of environmental entry for most APIs.

Standard aquatic ecotoxicological testing at Phase III covers three trophic levels, providing a representative picture of the range of potential effects across the aquatic ecosystem. The resulting toxicity data are used to derive the PNEC for the aquatic compartment, which is then compared with the PEC to generate the aquatic risk quotient.

If the aquatic risk quotient exceeds 1, further assessment or risk management consideration is required. If it remains below 1 and no other triggers are met, the aquatic ERA may be concluded at this phase.

Phase III covers:

  • Algal growth inhibition test (e.g. OECD 201)
  • Daphnia acute immobilisation test (e.g. OECD 202)
  • Daphnia reproduction test — chronic (e.g. OECD 211)
  • Fish acute toxicity test (e.g. OECD 203)
  • Fish early life stage test — chronic (e.g. OECD 210)
  • PNEC derivation for the aquatic compartment
  • Aquatic PEC/PNEC risk quotient assessment

IV

Phase IV — Sediment & Terrestrial Assessment

Phase IV extends the ecotoxicological assessment beyond the water column to address sediment and terrestrial compartments. This phase is triggered when the environmental fate assessment indicates significant partitioning to sediment or soil, or when the compound may reach terrestrial environments through relevant exposure pathways such as the land application of biosolids.

Sediment assessment evaluates the potential effects of the compound on organisms that live in or on sediment, which may be exposed to higher concentrations than aquatic organisms in the water column due to the partitioning behaviour of certain compounds. Terrestrial assessment covers the potential effects on soil invertebrates, plants and other organisms relevant to the terrestrial compartment.

PEC/PNEC risk quotients are derived for the sediment and terrestrial compartments separately, based on the compartment-specific PEC values from Phase II and PNEC values derived from Phase IV ecotoxicological data.

Phase IV covers:

  • Sediment organism toxicity testing (e.g. Chironomus, Lumbriculus)
  • Earthworm acute and reproduction toxicity
  • Soil plant toxicity
  • Soil microorganism inhibition
  • PNEC derivation for sediment and terrestrial compartments
  • Sediment and terrestrial PEC/PNEC risk quotient assessment

V

Phase V — Advanced Assessment

Phase V represents the most detailed tier of the ERA framework. It is triggered when earlier phases indicate potential concerns that cannot be resolved at lower tiers, or when the compound has properties suggesting bioaccumulation potential, significant transformation product formation or food-chain transfer.

At Phase V, the assessment addresses higher-tier environmental concerns that require more sophisticated study designs, extended exposure periods or consideration of indirect environmental effects through food-chain pathways. The phase concludes with a comprehensive final risk characterization that integrates all available ERA data.

The final PEC/PNEC assessment at Phase V uses the most refined exposure estimates and the most robust ecotoxicological dataset available, providing the strongest scientific basis for the overall ERA conclusion.

Phase V covers:

  • Bioaccumulation studies (BCF determination)
  • Food-chain transfer and secondary poisoning assessment
  • Transformation product identification and assessment
  • Higher-tier aquatic toxicity studies (e.g. mesocosm)
  • Refined PEC estimation using higher-tier models
  • Final PEC/PNEC assessment across all compartments
  • Comprehensive risk characterization and ERA conclusion
  • PBT/vPvB final determination

Putting the Framework Together

The Phase I–V ERA framework provides a coherent, scientifically structured pathway from initial screening to comprehensive environmental risk characterization. Each phase serves a specific purpose within the overall assessment:

  • Phase I establishes whether the compound has the potential to reach the environment at concentrations of concern
  • Phase II characterizes environmental fate and refines exposure estimates across all relevant compartments
  • Phase III establishes the aquatic hazard profile and derives the aquatic risk quotient
  • Phase IV extends hazard and risk assessment to sediment and terrestrial compartments
  • Phase V addresses advanced concerns including bioaccumulation, food-chain effects and transformation products, and delivers the final risk characterization

Not every pharmaceutical compound will require all five phases. The tiered structure ensures that assessment depth is proportionate to the evidence of environmental concern, with each phase’s conclusions determining whether further assessment is scientifically justified and regulatory required.


Accuprec Research Labs: Complete ERA Support

Accuprec Research Labs provides comprehensive support across the complete Phase I–V ERA framework for pharmaceutical compounds. Our integrated capabilities span Phase I screening, Phase II environmental fate studies, Phase III aquatic ecotoxicological testing, Phase IV sediment and terrestrial assessment, and Phase V advanced evaluation including bioaccumulation, transformation product assessment and final risk characterization.

We work within the EMA/OECD/GLP framework to ensure that studies and assessments meet the scientific and regulatory standards expected for pharmaceutical marketing authorisation submissions. Our team brings together expertise in environmental chemistry, ecotoxicology and regulatory science to deliver assessments that are scientifically rigorous, clearly structured and aligned with applicable guidance.

Whether your organization is initiating an ERA for a new active substance, expanding an existing assessment to address additional compartments or higher tiers, or preparing ERA documentation for a regulatory submission, Accuprec Research Labs can support your programme at every stage.

Partner with Accuprec Research Labs Pvt. Ltd. for complete Phase I–V Environmental Risk Assessment support for pharmaceutical compounds.


What do you think?
Leave a Reply

Your email address will not be published. Required fields are marked *

Insights

More Related Articles

Regulatory-Aligned Environmental Risk Assessment Support

Environmental Fate & Transformation Products: Understanding Pharmaceutical Compounds in the Environment 

Meet Accuprec at MEDICA 2026 Düsseldorf